Mutual of America Capital Management LLC reduced its holdings in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 5.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 147,068 shares of the company’s stock after selling 8,486 shares during the period. Mutual of America Capital Management LLC’s holdings in Pacira Pharmaceuticals were worth $7,228,000 at the end of the most recent reporting period.
Other hedge funds have also modified their holdings of the company. US Bancorp DE increased its stake in Pacira Pharmaceuticals by 40.7% in the 2nd quarter. US Bancorp DE now owns 6,038 shares of the company’s stock valued at $194,000 after buying an additional 1,746 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 1,925.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock valued at $214,000 after buying an additional 6,336 shares during the last quarter. Bouchey Financial Group Ltd acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth about $221,000. Boston Private Wealth LLC acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth about $246,000. Finally, Parametrica Management Ltd acquired a new position in shares of Pacira Pharmaceuticals during the 3rd quarter worth about $259,000. Hedge funds and other institutional investors own 97.84% of the company’s stock.
Shares of PCRX stock opened at $48.32 on Thursday. The stock has a market cap of $1.99 billion, a P/E ratio of -83.31, a P/E/G ratio of 82.60 and a beta of 1.65. The company has a quick ratio of 7.83, a current ratio of 8.66 and a debt-to-equity ratio of 0.95. Pacira Pharmaceuticals Inc has a 52 week low of $26.95 and a 52 week high of $55.00.
Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.40. The business had revenue of $83.45 million during the quarter, compared to the consensus estimate of $79.87 million. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. Pacira Pharmaceuticals’s revenue was up 23.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.11 EPS. On average, research analysts forecast that Pacira Pharmaceuticals Inc will post 0.02 EPS for the current year.
Several research analysts have recently weighed in on PCRX shares. TheStreet upgraded shares of Pacira Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Friday, August 10th. Canaccord Genuity restated a “hold” rating and set a $45.00 price objective on shares of Pacira Pharmaceuticals in a research note on Friday, August 17th. ValuEngine lowered shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Stifel Nicolaus started coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 13th. They set a “sell” rating and a $41.00 price objective on the stock. Finally, Royal Bank of Canada set a $55.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, September 19th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average target price of $53.76.
In other Pacira Pharmaceuticals news, Director Gary W. Pace acquired 4,000 shares of the business’s stock in a transaction on Wednesday, November 7th. The stock was purchased at an average price of $51.29 per share, with a total value of $205,160.00. Following the acquisition, the director now directly owns 28,319 shares of the company’s stock, valued at approximately $1,452,481.51. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Lauren Bullaro Riker sold 1,000 shares of the business’s stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $50.70, for a total transaction of $50,700.00. Following the completion of the sale, the vice president now directly owns 11,474 shares of the company’s stock, valued at approximately $581,731.80. The disclosure for this sale can be found here. Insiders have sold a total of 151,221 shares of company stock valued at $7,403,146 in the last ninety days. 5.90% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/12/06/mutual-of-america-capital-management-llc-sells-8486-shares-of-pacira-pharmaceuticals-inc-pcrx.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Read More: Market Capitalization
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.